April 2023 in “Journal of the American Academy of Dermatology” This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.
November 2025 in “Turkish Journal of Dermatology” In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.
April 2026 in “Meditsinskiy sovet = Medical Council” In this study, tofacitinib and baricitinib showed similar effectiveness and safety in treating alopecia areata, but baricitinib had a higher rate of early responders. Baseline hair loss severity was identified as the only independent predictor of treatment response.
February 2011 in “Annales de dermatologie et de vénéréologie” This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” This study found that Janus Kinase inhibitors, tofacitinib and baricitinib, showed effectiveness and safety in treating severe alopecia areata in a real-world setting, with optimal tolerability noted in younger individuals.
